Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104211 | 1.00 | EP300 (0.46) | EP300FAAHATMTSHRNAAA | |
| SCHEMBL7100787 | 0.97 | FAAH (0.48) | EP300FAAHTSHRNAAAHCAR2 | |
| SCHEMBL7100789 | 0.97 | FAAH (0.48) | EP300FAAHTSHRNAAAHCAR2 | |
| SCHEMBL7100073 | 0.95 | ATM (0.42) | EP300FAAHATMTSHRNAAA | |
| SCHEMBL7100076 | 0.95 | ATM (0.42) | EP300FAAHATMTSHRNAAA | |
| SCHEMBL7101399 | 0.94 | EP300 (0.46) | EP300FAAHATMTSHRNAAA | |
| SCHEMBL7101402 | 0.94 | EP300 (0.46) | EP300FAAHATMTSHRNAAA | |
| SCHEMBL7105792 | 0.94 | FAAH (0.44) | EP300FAAHATMTSHRNAAA | |
| SCHEMBL7105793 | 0.94 | FAAH (0.44) | EP300FAAHATMTSHRNAAA | |
| SCHEMBL7107499 | 0.92 | ATM (0.42) | EP300FAAHATMTSHRNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000939-B1 | Producing z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL CO (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-6403572-B1 | REACTING ACID SALT OF A 2-AMINOTHIAZOLE COMPOUND WITH INORGANIC ACID | SUMITOMO CHEMICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020058818-A1 | Producing Z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL CO., LTD. | 2002-05-16 | — | — | US | disclosed |
| US-6340763-B1 | SALT FORMATION AND CRYSTALLIZATION, REACTION OF HALOGENATED COMPOUND AND THIOUREA COMPOUND | SUMITOMO CHEMICAL CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1000939-A1 | Producing z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058818-A1 | Producing Z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | ZYX, H1-0, HAO2 | EP300 2578/4885FAAH 4261/4885ATM 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.